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Objective To determine whether the standard deviation of nuchal translucency (NT) measurements
has decreased over time and if so to revise the estimate and assess the effect of revising the
estimate of the standard deviation on the performance of antenatal screening for Down’s syndrome.
Setting Data from a routine antenatal screening programme for Down’s syndrome comprising 106
affected and 22,640 unaffected pregnancies.
Methods NT measurements were converted into multiple of the median (MoM) values and standard
deviations of log10 MoM values were calculated in affected and unaffected pregnancies. The
screening performance of the Combined and Integrated tests (that include NT measurement) were
compared using previous and revised estimates of the standard deviation.
Results The standard deviation of NT in unaffected pregnancies has reduced over time (from 1998
to 2008) (e.g. from 0.1329 to 0.1105 [log10 MoM] at 12–13 completed weeks of pregnancy,
reducing the variance by about 30%). This was not observed in affected pregnancies. Compared
with results from the serum, urine and ultrasound screening study (SURUSS), use of the revised NT
standard deviations in unaffected pregnancies resulted in an approximate 20% decrease in the
false-positive rate for a given detection rate; for example, from 2.1% to 1.7% (a 19% reduction) at
a 90% detection rate using the Integrated test with ﬁrst trimester markers measured at 11 completed
weeks’ gestation and from 4.4% to 3.5% (a 20% reduction) at an 85% detection rate using the
Combined test at 11 completed weeks.
Conclusions The standard deviation of NT has declined over time and using the revised estimates
improves the screening performance of tests that incorporate an NT measurement.
INTRODUCTION
N
uchal translucency (NT) is useful as an antenatal
screening marker for Down’s syndrome in the late
ﬁrst trimester of pregnancy. It forms part of the
Combined test (NT and serum markers pregnancy-
associated plasma protein-A [PAPP-A] and free b-human
chorionic gonadotrophin [free b-hCG] measured between
10 and 13 weeks gestation) and part of the Integrated test
(NT and PAPP-A measured between 10 and 13 weeks and
serum markers alphafetoprotein, unconjugated oestriol,
free b-hCG and inhibin-A measured between 14 and 22
weeks gestation).
In monitoring our screening programme at the Wolfson
Institute of Preventive Medicine, London, there was an indi-
cation that the standard deviation of NT in unaffected preg-
nancies decreased over time. This prompted us to investigate
the observation further to obtain a revised estimate of the
standard deviation. We then investigated the impact of the
revised standard deviation on screening performance com-
pared with results from the Serum, Urine and Ultrasound
Screening Study (SURUSS).
1
METHODS
We used data from 22,719 women who attended two
London antenatal clinics (at University College Hospital
and the Whittington Hospital) between January 2003 and
December 2008 for antenatal screening for Down’s syn-
drome using the Combined or Integrated tests. The tests
were performed at the Wolfson Institute of Preventive
Medicine. We also included data from 27 women who
were not offered these screening tests because of high NT
measurements and whose pregnancies were subsequently
diagnosed as being affected with Down’s syndrome
(median NT 4.9 mm). Down’s syndrome pregnancies were
recorded from the two hospitals, the regional cytogenetic
unit and the National Down Syndrome Cytogenetic Register.
NT values were converted into multiple of the median
(MoM) values by dividing measured NT values by the
expected NT for a given crown rump length (CRL) (obtained
from a log–linear regression of median log NT measurements
against median CRL measurements in 5 mm categories of
CRL [weighted by the number of women in each category]).
Table 1 gives details of the pregnancies used in our analyses.
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and the median NT MoM values according to gestational age
were calculated in Down’s syndrome and unaffected preg-
nancies. Gestational age was estimated from CRL using the
equation reported by Robinson and Fleming.
2
Screening performance was expressed as detection rates
for speciﬁed false-positive rates, false-positive rates for speci-
ﬁed detection rates and detection and false-positive rates for
speciﬁed risk cut-offs. For the Combined and Integrated
tests, screening performance was estimated for the popu-
lation of maternities in England and Wales 1996–1998,
3
for comparison with published estimates from SURUSS.
1
Detection and false-positive rates were estimated by
numerical integration of the multivariate Gaussian distri-
butions of MoM values in Down’s syndrome and unaffected
pregnancies, using the maternal age distribution and distri-
bution parameters (means, standard deviations and
correlation coefﬁcients) for serum markers previously pub-
lished
1,4,5 except for the standard deviation of NT in unaf-
fected pregnancies, which was found to be signiﬁcantly
lower than estimates made in studies conducted in the past
and the truncation limits for NT (see the Results). The
median NT MoM values and standard deviations in
Down’s syndrome pregnancies were similar to those pre-
viously reported, so it was not necessary to revise these
(see the Results). Screening performance estimates apply
to the detection of Down’s syndrome in the early second tri-
mester. Too few data are available on affected pregnancies at
10 weeks, so screening performance was estimated for 11,
12 and 13 completed weeks of gestation only.
RESULTS
Table 2 shows the expected median MoM values (regressed)
and standard deviations of the (log10) MoM value in Down’s
syndrome and unaffected pregnancies in this study com-
pared with those reported in SURUSS.
1 The standard devi-
ations in unaffected pregnancies were lower than those
reported in SURUSS (the standard deviations at 12 and 13
weeks were similar [0.1096 and 0.1109, respectively], and
therefore combined). In Down’s syndrome pregnancies,
the median MoM values and standard deviation were
similar to those reported in SURUSS.
Figure 1 shows the relative frequency distributions of NT
in Down’s syndrome and unaffected pregnancies using
previous estimates of the standard deviation in unaffected
pregnancies and revised estimates at 11, 12 and 13 completed
weeks’ gestation. As a single screening test considered
without maternal age, NT alone has revised detection rates
of 71%, 68% and 61% for a 5% false-positive rate at 11,
12 and 13 completed weeks, respectively, compared with
previous estimates of 67%, 63% and 55%, respectively.
1
Truncation limits for NT (also given in Table 2) were
Table 1 Maternal and gestational age, and NT in Down’s
syndrome and unaffected pregnancies
Down’s syndrome Unaffected
Median age (years) 39 34
Median CRL (mm) 63 62
Gestational age
10 weeks gestation 2 243
11 weeks gestation 20 4270
12 weeks gestation 50 10,363
13 weeks gestation 34 7764
Total 106 22,640
Median NT (mm) 2.7 1.5
Median NT (MoM)
10 weeks gestation 3.93 1.02
11 weeks gestation 2.22 0.98
12 weeks gestation 1.86 1.02
13 weeks gestation 1.55 0.99
CRL, crown rump length; NT, nuchal translucency, MoM, multiple of the median
Table 2 Median, standard deviation and truncation limits of NT MoM values in Down’s syndrome and unaffected pregnancies:
estimates from the present study and estimates from SURUSS
1,4,5
Estimates from present study Estimates from SURUSS
Down’s syndrome
pregnancies
Unaffected
pregnancies
Down’s syndrome
pregnancies
Unaffected
pregnancies
Median NT MoM (regressed)
10 completed weeks 2.86 1 2.42 1
11 completed weeks 2.29 1 2.18 1
12 completed weeks 1.84 1 1.96 1
13 completed weeks 1.47 1 1.77 1
Standard deviation (log10 MoM)
10 completed weeks )
0:2382
0.1550 } 0.2313 0.1732
11 completed weeks 0.1275
† 0.1439
†
12 completed weeks 0.1105
† 0.1329
†
13 completed weeks
Trunction limits (MoM)
10 completed weeks 0.50–2.50 )
0:65–2:50
11 completed weeks 0.70–2.50
12 completed weeks 0.80–2.50
13 completed weeks 0.85–2.50
NT, nuchal translucency; SURUSS, Serum, Urine and Ultrasound Screening Study; MoM, multiple of the median
P ¼ 0.024
†P , 0.001
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(NT) multiple of the median (MoM) values in Down’s syndrome and
unaffected pregnancies according to gestational age. Solid line is
previous distribution and dashed line is revised distribution. Median
MoM in Down’s syndrome pregnancies at vertical line
Figure 2 Probability plots of nuchal translucency in unaffected
pregnancies according to week of gestation
Table 3 Screening performance estimates of NT, Combined test and Integrated test according to completed week of ﬁrst trimester
measurements: estimates with revised standard deviations and truncation limits and estimates using SURUSS parameters
Screening test
(include maternal age)
Estimates using revised unaffected standard
deviations and revised truncation limits Estimates using SURUSS parameters
1,4,5
DR (%) for FPR of FPR (%) for DR of DR (%) for FPR of FPR (%) for DR of
1% 3% 5% 75% 80% 85% 90% 1% 3% 5% 75% 80% 85% 90%
Combined test
11 completed weeks 76 84 87 0.94 1.8 3.5 7.4 72 82 86 1.4 2.4 4.4 8.5
12 completed weeks 74 82 86 1.2 2.3 4.5 9.3 69 79 84 1.9 3.3 6.0 11
13 completed weeks 69 78 83 2.0 3.6 6.4 12 64 76 81 2.8 4.6 7.7 14
Integrated test
11 completed weeks 87 93 95 0.13 0.27 0.64 1.7 86 92 94 0.20 0.41 0.87 2.1
12 completed weeks 86 92 94 0.16 0.37 0.88 2.3 83 90 93 0.30 0.61 1.3 3.0
13 completed weeks 82 89 92 0.35 0.73 1.6 3.6 80 88 91 0.55 1.1 2.1 4.4
SURUSS, Serum, Urine and Ultrasound Screening Study; NT, nuchal translucency; DR, detection rate; FPR, false-positive rate
10 Bestwick et al.
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Figure 2) and to prevent the reversal of risk at lower NT
MoM values
4 (i.e. risk of Down’s syndrome decreasing
with smaller NT measurements and then increasing with
further decreases in NT).
Table 3 shows the effect of the revised distribution par-
ameters based on the decreased NT standard deviation in
unaffected pregnancies and the revised truncation limits
compared with those from SURUSS on the screening per-
formance of the Combined test at 11, 12 and 13 completed
weeks’ gestation and the Integrated test with ﬁrst-stage
measurements at 11, 12 and 13 completed weeks’ gestation.
The revised false-positive rates for a given detection rate are
about 20% lower than previous estimates. For example, at an
85% detection rate the false-positive rate using the
Combined test at 11 completed weeks’ gestation is 3.5%
instead of 4.4% (or about 9 fewer false-positives per 1000
women screened), and at a 90% detection rate using the
Integrated test with ﬁrst-stage measurements at 11 completed
weeks’ gestation, the false-positive rate is 1.7% instead of
2.1% (4 fewer false-positives per 1000 women screened).
The relative reduction in the false-positive rate is greater at
lower detection rates; for example, at an 80% detection rate
the false-positive rate is reduced by 25% (from 2.4% to
1.8%) with the Combined test at 11 completed weeks.
Table 4 shows screening performance of the Combined
and Integrated tests using the revised and the previous
estimates according to risk cut-off.
DISCUSSION
The standard deviation of NT in unaffected pregnancies has
decreased over time. At 12–13 weeks gestation, our revised
standard deviation of log10 NT MoM (0.1105) represents a
17% decrease in the standard deviation or a 31% decrease
in the variance compared with the standard deviation
reported in 2003 in SURUSS (0.1329).
1 Data from the
Fetal Medicine Foundation show a similar trend; an estimate
of the standard deviation in unaffected pregnancies in 1998
was 0.120,
6 compared with 0.097 in 2008 (from Figure 4 of
Wright et al.
7), a similar decrease in the standard deviation of
19% or decrease in the variance of 35%. The explanation
for this decrease is uncertain; it could be a result of greater
magniﬁcation of the fetal image with improvements in
instrumentation together with sonographers having
become more experienced in the measurement of NT.
A declining trend in the standard deviation in Down’s syn-
drome pregnancies was not observed, perhaps because NT
tends to be large in such pregnancies, so precise measure-
ments would have been possible anyway. There were too
few data to examine whether the standard deviation
decreased with gestation as it did in unaffected pregnancies.
Exclusion of data from women in whom clinical action was
taken on grounds of a high NT alone results in a smaller
standard deviation (0.17 compared with 0.24 for all
women), but to provide accurate risks of having an affected
pregnancy it is necessary to use the standard deviation based
on all women.
When a screening marker has different standard deviations
in affected and unaffected pregnancies risk reversal will occur,
and if they are markedly different it will occur within non-
extreme values of the marker.
4 Accordingly, it is reasonable
to set truncation limits near the point of risk reversal.
Previously, a single lower truncation limit was suggested
(0.65 MoM), but with the smaller standard deviation in unaf-
fected pregnancies, it is necessary to have week-speciﬁc lower
truncation limits to avoid the phenomenon of risk reversal.
The previously reported upper truncation limit of 2.5 MoM
from 10 to 13 weeks is still applicable.
The improvement in screening performance shown in
Table 3 that arises from the smaller standard deviations of
NT in unaffected pregnancies, while small is clinically
useful – an approximate reduction in the false-positive
rate of 20% or about four fewer false-positive per 1000
women screened without a reduction in the detection rate.
The improvement in estimated screening performance was
similar for the Combined and Integrated tests.
...............
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